Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

462 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design.
Berruti A, Bitossi R, Gorzegno G, Bottini A, Alquati P, De Matteis A, Nuzzo F, Giardina G, Danese S, De Lena M, Lorusso V, Farris A, Sarobba MG, DeFabiani E, Bonazzi G, Castiglione F, Bumma C, Moro G, Bruzzi P, Dogliotti L; Epirubicin-Lonidamine Group, Orbassano, Torino, Italy. Berruti A, et al. Among authors: farris a. J Clin Oncol. 2002 Oct 15;20(20):4150-9. doi: 10.1200/JCO.2002.08.012. J Clin Oncol. 2002. PMID: 12377958 Clinical Trial.
Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients.
Tampellini M, Berruti A, Bitossi R, Gorzegno G, Alabiso I, Bottini A, Farris A, Donadio M, Sarobba MG, Manzin E, Durando A, Defabiani E, De Matteis A, Ardine M, Castiglione F, Danese S, Bertone E, Alabiso O, Massobrio M, Dogliotti L. Tampellini M, et al. Among authors: farris a. Breast Cancer Res Treat. 2006 Aug;98(3):241-8. doi: 10.1007/s10549-005-9155-y. Epub 2006 May 3. Breast Cancer Res Treat. 2006. PMID: 16670941
Combination regimen of epirubicin, vinorelbine and 5-fluorouracil continuous infusion as first-line chemotherapy in anthracycline-naive metastatic breast cancer patients.
Berruti A, Bitossi R, Bottini A, Bonardi S, Donadio M, Nigro C, Bertetto O, Danese S, Bertone E, Sarobba MG, Farris A, Katsaros D, Castiglione F, Volpe T, Lattuada S, Mancarella S, Dogliotti L. Berruti A, et al. Among authors: farris a. Eur J Cancer. 2005 Jan;41(2):249-55. doi: 10.1016/j.ejca.2004.07.003. Eur J Cancer. 2005. PMID: 15661550 Clinical Trial.
Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines.
Berruti A, Bitossi R, Gorzegno G, Bottini A, Generali D, Milani M, Katsaros D, Rigault de la Longrais IA, Bellino R, Donadio M, Ardine M, Bertetto O, Danese S, Sarobba MG, Farris A, Lorusso V, Dogliotti L. Berruti A, et al. Among authors: farris a. Br J Cancer. 2005 Feb 28;92(4):634-8. doi: 10.1038/sj.bjc.6602335. Br J Cancer. 2005. PMID: 15668714 Free PMC article. Clinical Trial.
Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial.
Dogliotti L, Berruti A, Buniva T, Zola P, Baù MG, Farris A, Sarobba MG, Bottini A, Alquati P, Deltetto F, Gosso P, Monzeglio C, Moro G, Sussio M, Perroni D. Dogliotti L, et al. Among authors: farris a. J Clin Oncol. 1996 Apr;14(4):1165-72. doi: 10.1200/JCO.1996.14.4.1165. J Clin Oncol. 1996. PMID: 8648371 Clinical Trial.
Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial.
Italian Multicentre Breast Study with Epirubicin; Ambrosini G, Balli M, Garusi G, Demicheli R, Jirillo A, Bonciarelli G, Bruscagnin G, Fila G, Bumma C, Lacroix F, Buzzi F, Di Costanzo F, Padalino D, Brugia M, Calabresi F, Natali M, Cartei G, Chiesa G, Blasina B, Ciambellotti E, Moro G, D'Aquino S, Altavilla G, Adamo V, De Maria D, Falchi AM, Bertoncelli P, Farris A, Fiorentino M, Fornasiero A, Fosser V, Daniele O, Foggi CM, Speranza GB, Sartori S, Camilluzzi E, Gallo L, Poggio R, Secondo V, Gambi A, Grignani F, Capodicasa E, Lopez M, Papaldo P, Di Lauro L, Vici P, Marenco G, Folco U, Bonanni F, Marsilio P, Palazzotto G, Di Carlo A, Cusimano MP, Pastorino G, Puccetti C, Giusto M, Rausa L, Gebbia N, Palmeri S, D'Alessandro N, Saccani F, Becchi G, Schieppati G, Spinelli I, Tagliagambe A, Tonato M, Minotti V, Ardia A, Viaro D, De Micheli P, Zingali G, Sacchetti G, Intini C. Italian Multicentre Breast Study with Epirubicin, et al. Among authors: farris a. J Clin Oncol. 1988 Jun;6(6):976-82. doi: 10.1200/JCO.1988.6.6.976. J Clin Oncol. 1988. PMID: 2897433 Clinical Trial.
Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease.
Tampellini M, Berruti A, Gerbino A, Buniva T, Torta M, Gorzegno G, Faggiuolo R, Cannone R, Farris A, Destefanis M, Moro G, Deltetto F, Dogliotti L. Tampellini M, et al. Among authors: farris a. Br J Cancer. 1997;75(5):698-702. doi: 10.1038/bjc.1997.124. Br J Cancer. 1997. PMID: 9043027 Free PMC article.
Prognostic factors in metastatic breast cancer patients obtaining objective response or disease stabilization after first-line chemotherapy with epirubicin. Evidence for a positive effect of maintenance hormonal therapy on overall survival.
Berruti A, Zola P, Buniva T, Baù MG, Farris A, Sarobba MG, Bottini A, Tampellini M, Durando A, Destefanis M, Monzeglio C, Moro G, Sussio M, Perroni D, Dogliotti L. Berruti A, et al. Among authors: farris a. Anticancer Res. 1997 Jul-Aug;17(4A):2763-8. Anticancer Res. 1997. PMID: 9252712 Clinical Trial.
Independent factors predict supranormal CA 15-3 serum levels in advanced breast cancer patients at first disease relapse.
Tampellini M, Berruti A, Gorzegno G, Bitossi R, Bottini A, Durando A, De Matteis A, Farris A, Donadio M, De Fabiani E, Manzin E, Arese P, Sarobba MG, Castiglione F, Moro G, Bonazzi G, Nuzzo F, Massobrio M, Dogliotti L. Tampellini M, et al. Among authors: farris a. Tumour Biol. 2001 Nov-Dec;22(6):367-73. doi: 10.1159/000050639. Tumour Biol. 2001. PMID: 11786730
462 results